Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHA:603896)

SHA:603896 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	627.82	677.92	770.34	817.67	759.99	629.84
Other Revenue	13.76	13.76	14.01	11.4	7.15	6.21
Revenue	641.59	691.68	784.35	829.07	767.14	636.05
Revenue Growth (YoY)	-19.71%	-11.81%	-5.39%	8.07%	20.61%	16.33%
Cost of Revenue	126.99	133.35	135.53	129.21	126.37	105.67
Gross Profit	514.6	558.34	648.82	699.86	640.76	530.38
Selling, General & Admin	367.47	390.75	403.79	405.17	397.19	336.38
Research & Development	48.89	48.41	49.68	47.82	50.82	48.49
Other Operating Expenses	-15.45	-2.21	-4.52	6.84	7.67	5.34
Operating Expenses	397.42	436.85	447.73	461.41	456.47	390.67
Operating Income	117.17	121.49	201.09	238.45	184.3	139.71
Interest Expense	-13.42	-14.78	-24.7	-13.03	-10.17	-11.72
Interest & Investment Income	22.88	36.84	51.77	29.99	31	20.29
Other Non Operating Income (Expenses)	1.89	-0.47	-0.43	-0.68	-0.56	-0.5
EBT Excluding Unusual Items	128.53	143.08	227.72	254.73	204.57	147.79
Gain (Loss) on Sale of Investments	6.37	4.63	0.27	-1.26	-12.33	-4.91
Gain (Loss) on Sale of Assets	3.12	8.81	0.17	0.07	0.03	-
Asset Writedown	-0.02	-0.02	-0.03	-0.06	-0	-0
Other Unusual Items	18.22	18.22	26.77	24.48	8.79	10.83
Pretax Income	156.22	174.73	254.91	277.97	201.06	153.7
Income Tax Expense	0.26	0.01	0.43	0.45	0.75	1.99
Earnings From Continuing Operations	155.96	174.71	254.48	277.51	200.31	151.71
Minority Interest in Earnings	-	-	-	0.27	0.52	-
Net Income	155.96	174.71	254.48	277.78	200.83	151.71
Net Income to Common	155.96	174.71	254.48	277.78	200.83	151.71
Net Income Growth	-42.02%	-31.34%	-8.39%	38.32%	32.37%	22.45%
Shares Outstanding (Basic)	199	199	196	194	191	184
Shares Outstanding (Diluted)	199	199	196	194	191	184
Shares Change (YoY)	1.60%	1.42%	0.77%	1.56%	3.77%	0.70%
EPS (Basic)	0.78	0.88	1.30	1.43	1.05	0.82
EPS (Diluted)	0.78	0.88	1.30	1.43	1.05	0.82
EPS Growth	-42.94%	-32.31%	-9.09%	36.19%	27.57%	21.60%
Free Cash Flow	-173.18	-293.62	-99.48	158.68	135.07	191.38
Free Cash Flow Per Share	-0.87	-1.48	-0.51	0.82	0.71	1.04
Dividend Per Share	0.270	0.270	0.390	0.440	0.311	0.240
Dividend Growth	-30.77%	-30.77%	-11.36%	41.25%	29.79%	-9.57%
Gross Margin	80.21%	80.72%	82.72%	84.41%	83.53%	83.39%
Operating Margin	18.26%	17.56%	25.64%	28.76%	24.02%	21.96%
Profit Margin	24.31%	25.26%	32.45%	33.51%	26.18%	23.85%
Free Cash Flow Margin	-26.99%	-42.45%	-12.68%	19.14%	17.61%	30.09%
EBITDA	181.13	185.96	267.62	295.78	233.47	183.05
EBITDA Margin	28.23%	26.88%	34.12%	35.68%	30.43%	28.78%
D&A For EBITDA	63.96	64.47	66.53	57.33	49.17	43.34
EBIT	117.17	121.49	201.09	238.45	184.3	139.71
EBIT Margin	18.26%	17.56%	25.64%	28.76%	24.02%	21.96%
Effective Tax Rate	0.17%	0.01%	0.17%	0.16%	0.37%	1.29%
Revenue as Reported	641.59	691.68	784.35	829.07	767.14	636.05
Advertising Expenses	-	190.46	201.21	201.3	198.54	170.35

Source: S&P Global Market Intelligence. Standard template. Financial Sources.